offline
Healthcare | Biotechnology | USA
This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales
Late Tuesday, Vertex Pharmaceuticals (VRTX) topped fourth-quarter sales and earnings forecasts as revenue from the biotech's cystic fibrosis treatments jumped by 40%. Vertex stock rose in late action.
For the fourth quarter, Vertex earnings of $1.30 per share, minus certain items, spiked 113% year over year. That beat estimates from analysts polled by Zacks Investment Research, which called for Vertex earnings of $1.05 per share, on an adjusted basis.
Total revenue popped nearly 34% to $870.11 million.
...
https://www.investors.com/news/technolog...yptr=yahoo
VRTX nachbörslich +2,6 % auf 192
![[Bild: VRTXc1dl1712.png]](https://finviz.com/publish/020519/VRTXc1dl1712.png)
This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales
Late Tuesday, Vertex Pharmaceuticals (VRTX) topped fourth-quarter sales and earnings forecasts as revenue from the biotech's cystic fibrosis treatments jumped by 40%. Vertex stock rose in late action.
For the fourth quarter, Vertex earnings of $1.30 per share, minus certain items, spiked 113% year over year. That beat estimates from analysts polled by Zacks Investment Research, which called for Vertex earnings of $1.05 per share, on an adjusted basis.
Total revenue popped nearly 34% to $870.11 million.
...
https://www.investors.com/news/technolog...yptr=yahoo
VRTX nachbörslich +2,6 % auf 192
